Tags

Type your tag names separated by a space and hit enter

An assessment by the Statin Intolerance Panel: 2014 update.
J Clin Lipidol 2014 May-Jun; 8(3 Suppl):S72-81JC

Abstract

This article from the National Lipid Association Statin Intolerance Panel provides a framework for understanding statin intolerance and makes general recommendations for health professionals. For specific guidance on adverse events related to muscle, liver, cognition, and glucose metabolism, one should refer to the other reports of the Statin Safety Task Force for those topics. Although statin adverse effects rarely lead to permanent sequelae, symptomatic intolerance frequently hinders cardiovascular risk reduction by statins. We emphasize here the advisory role of the clinician helping each patient to make personal decisions on statin tolerability. We identify a pressing need for further research on statin intolerance and make suggestions for research design.

Authors+Show Affiliations

Division of Endocrinology, Diabetes, and Metabolism, Duke University Medical Center, 201 Trent Drive, Baker House 281, Durham, NC 27710, USA. Electronic address: john.guyton@duke.edu.Louisville Metabolic and Atherosclerosis Research Center, Louisville KY, USA.Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX, USA.Office of Health Promotion and Disease Prevention, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.No affiliation info available

Pub Type(s)

Journal Article
Practice Guideline

Language

eng

PubMed ID

24793444

Citation

Guyton, John R., et al. "An Assessment By the Statin Intolerance Panel: 2014 Update." Journal of Clinical Lipidology, vol. 8, no. 3 Suppl, 2014, pp. S72-81.
Guyton JR, Bays HE, Grundy SM, et al. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S72-81.
Guyton, J. R., Bays, H. E., Grundy, S. M., Jacobson, T. A., & The National Lipid Association Statin Intolerance Panel, . (2014). An assessment by the Statin Intolerance Panel: 2014 update. Journal of Clinical Lipidology, 8(3 Suppl), pp. S72-81. doi:10.1016/j.jacl.2014.03.002.
Guyton JR, et al. An Assessment By the Statin Intolerance Panel: 2014 Update. J Clin Lipidol. 2014;8(3 Suppl):S72-81. PubMed PMID: 24793444.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An assessment by the Statin Intolerance Panel: 2014 update. AU - Guyton,John R, AU - Bays,Harold E, AU - Grundy,Scott M, AU - Jacobson,Terry A, AU - The National Lipid Association Statin Intolerance Panel,, PY - 2014/03/03/received PY - 2014/03/04/accepted PY - 2014/5/6/entrez PY - 2014/5/6/pubmed PY - 2014/12/17/medline KW - Drug intolerance KW - Patient-centered medicine KW - Statin adverse effects KW - Statin safety KW - Statins SP - S72 EP - 81 JF - Journal of clinical lipidology JO - J Clin Lipidol VL - 8 IS - 3 Suppl N2 - This article from the National Lipid Association Statin Intolerance Panel provides a framework for understanding statin intolerance and makes general recommendations for health professionals. For specific guidance on adverse events related to muscle, liver, cognition, and glucose metabolism, one should refer to the other reports of the Statin Safety Task Force for those topics. Although statin adverse effects rarely lead to permanent sequelae, symptomatic intolerance frequently hinders cardiovascular risk reduction by statins. We emphasize here the advisory role of the clinician helping each patient to make personal decisions on statin tolerability. We identify a pressing need for further research on statin intolerance and make suggestions for research design. SN - 1933-2874 UR - https://www.unboundmedicine.com/medline/citation/24793444/An_assessment_by_the_Statin_Intolerance_Panel:_2014_update_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1933-2874(14)00158-5 DB - PRIME DP - Unbound Medicine ER -